English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, January 12, 2021
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
エーザイ、米国臨床腫瘍学会消化器がんシンポジウムにおいてレンバチニブに関する演題を発表
Thursday, December 24, 2020
エーザイ、人事異動ならびに組織改編(2021年1月1日付)を発表
Friday, December 18, 2020
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
エーザイ、川島工園に第5製剤棟が竣工 抗がん剤「レンビマ(R)」製剤の自社生産機能を強化
Thursday, December 17, 2020
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
エーザイ、進行性子宮内膜がんを対象としたレンビマとキイトルーダ併用療法の臨床第III相試験について発表
Friday, December 11, 2020
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
Thursday, December 10, 2020
アデュカヌマブ、日本において新薬承認を申請
Friday, December 4, 2020
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575